Advances in the treatment of high-risk multiple myeloma

At the Myeloma 2015 meeting, Prof Michele Cavo (Bologna University School of Medicine, Bologna, Italy) discusses the heterogeneity and treatment recommendations for high-risk multiple myeloma. Emerging therapeutic strategies in clinical development, including lenalidomide and bortezomib-based treatment regimens, are showing promising activity for this patient group.

Share this video  
11th April 2015